IXICO (LON:IXI) Stock Price Down 6.6% – Time to Sell?

IXICO plc (LON:IXI) shares dropped 6.6% during mid-day trading on Tuesday . The company traded as low as GBX 7.47 and last traded at GBX 7.47. 120,638 shares changed hands during trading, an increase of 8% from the average session volume of 111,293 shares. The stock had previously closed at GBX 8.

IXICO Price Performance

The stock has a market cap of £16.64 million, a PE ratio of -3.90, a price-to-earnings-growth ratio of -0.38 and a beta of 0.13. The company has a quick ratio of 4.90, a current ratio of 2.83 and a debt-to-equity ratio of 5.22. The company’s fifty day moving average is GBX 8.32 and its 200 day moving average is GBX 8.18.

IXICO (LON:IXI) last released its quarterly earnings data on Tuesday, May 19th. The company reported GBX (1.21) earnings per share (EPS) for the quarter. IXICO had a negative return on equity of 16.18% and a negative net margin of 24.98%.The business had revenue of GBX 395 million for the quarter. As a group, sell-side analysts anticipate that IXICO plc will post -289.3584879 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other IXICO news, insider Mark Warne purchased 50,006 shares of the firm’s stock in a transaction that occurred on Wednesday, July 15th. The stock was purchased at an average cost of GBX 8 per share, with a total value of £4,000.48. Company insiders own 3.07% of the company’s stock.

IXICO Company Profile

IXICO is a global leader in neuroscience imaging and biomarker analytics, using its proprietary AI-driven platform to help advance the treatment of neurological disorders and reduce the uncertainties associated with drug discovery, development and monitoring.

By unlocking valuable insights into drug safety and efficacy, IXICO has built a global reputation and 20-year track record as an end-to-end Imaging Contract Research Organisation (iCRO) managing and analysing neurological clinical trials.